Recent programs aiming at the development of non-invasive AD biomarkers reached important achievements by employing plasma Aβ 40-42 (Neurology 3-Plex A-performed with SIMOA technology [3]), plasma phosphorylated tau 217 and tau181, and the Lumipulse G β-Amyloid Ratio (42/40) [4]. The gene discussed is MAPT; the disease is Alzheimer disease.